# A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

> **NCT00870870** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 64 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **BIOLOGICAL:** IMC-A12 (cixutumumab)
- **BIOLOGICAL:** Cetuximab
- **BIOLOGICAL:** IMC-A12 (cixutumumab)
- **BIOLOGICAL:** Cetuximab
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00870870
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2018-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00870870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00870870, "A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00870870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*